Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
How to Develop and Implement a National Drug Policy (Second Edition)
(2001; 96 pages) [French] [Spanish] View the PDF document
Table of Contents
View the documentContributors
View the documentAbbreviations and acronyms
View the documentPreface
Open this folder and view contentsPart I: How to develop and implement a national drug policy
Open this folder and view contentsPart II: Key components of a national drug policy
View the documentReferences
View the documentSelected WHO publications and documents of related interest
View the documentBack cover
 

References

1. WHO. Guidelines for developing national drug policies. Geneva: World Health Organization; 1988.

2. WHO. WHO medicines strategy. Framework for action in essential drugs and medicines policy 2002-2003. Geneva: World Health Organization; 2000. WHO/EDM/2000.1.

3. WHO. Contribution to updating the WHO guidelines for developing national drug policies. Report of the WHO Expert Committee on National Drug Policies. Geneva: World Health Organization; 1995. WHO/DAP/95.9.

4. Reich M. Bangladesh pharmaceutical policy and politics. Health Policy and Planning 1994; 9(2): 130-143.

5. Lee MB. The politics of pharmaceutical reform: the case of the Philippine National Drug Policy. International Journal of Health Services 1994; 4: 477-494.

6. Dag Hammarskjöld Foundation. Making national drug policies a development priority: a strategy paper and six country stories. Development Dialogue 1995; 1: 1-256.

7. WHO Medicines web site at: http://www.who.int/medicines

8. Quick JD, Rankin JR, Laing RO, O’Connor RW, Hogerzeil HV, Dukes MNG, Garnett A, editors. Managing Drug Supply. 2nd ed. West Hartford, USA: Kumarian Press; 1997.

9. Brudon-Jakobowicz P, Rainhorn J-D, Reich MR. Indicators for monitoring national drug policies. A practical manual. 2nd ed. Geneva: World Health Organization; 1999. WHO/EDM/PAR/99.3.

10. MSH/RPM. Rapid pharmaceutical management assessment: an indicator-based approach. Washington D.C.: Management Sciences for Health, Rapid Pharmaceutical Management Project; 1995.

11. WHO. Core indicators for monitoring national drug policies. Geneva: World Health Organization. In preparation.

12. Trap B, Chinyanganya F, Hogerzeil HV, Nathoo KJ, Chidarikire A. How to support a national essential drugs programme by repeated surveys of the pharmaceutical sector: the Zimbabwe experience. Geneva: World Health Organization. In print.

13. Brudon-Jakobowicz P. Comparative analysis of national drug policies. EDM Research Series No.25. Geneva: World Health Organization; 1997. WHO/DAP/97.6.

14. WHO. The world drug situation. Geneva: World Health Organization;1988. Second edition in preparation.

15. WHO. The use of essential drugs. Ninth report of the WHO Expert Committee (including the 11th WHO Model List of Essential Drugs). WHO Technical Report Series No.895. Geneva: World Health Organization; 2000. The List is also available on the WHO Medicines web site: http://www.who.int/medicines/edl.html

16. Grimshaw J, Russell IT. Effect of clinical guidelines on medical practice: a systematic overview of rigorous evaluations. Lancet 1993; ii: 1317-1322.

17. WHO. Guidelines for drug donations, 2nd ed. Interagency guidelines. Geneva: World Health Organization; 1999. WHO/EDM/PAR/99.4.

18. WHO. The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 1997. WHO/EDM/QSM/99.6.

19. WHO. Guidelines for the assessment of herbal medicines. WHO Technical Report Series No.863, Annex 11. Geneva: World Health Organization; 1996.

20. WHO. Good manufacturing practices. Supplementary guidelines for the manufacture of herbal medicinal products. WHO Technical Report Series No.863, Annex 8. Geneva: World Health Organization; 1996.

21. WHO. Quality control methods for medicinal plant materials. Geneva: World Health Organization; 1998.

22. WHO. Basic tests for drugs: pharmaceutical substances, medicinal plant materials and dosage forms. Geneva: World Health Organization; 1998.

23. WHO. General guidelines for methodologies on research and evaluation of traditional medicine. Geneva: World Health Organization; 2000. WHO/EDM/TRM/2000.1.

24. WHO. WHO monographs on selected medicinal plants. Volume 1. Geneva: World Health Organization; 1999. (Volumes 2 and 3 in print).

25. WHO. Regulatory situation of herbal medicines: a worldwide review. Geneva: World Health Organization; 1998: WHO/TRM/98.1.

26. Bennett S, Quick JD, Velásquez G. Public-private roles in the pharmaceutical sector. Implications for equitable access and rational drug use. Health Economics and Drugs, EDM Series No.5. Geneva: World Health Organization; 1997. WHO/DAP/97.12.

27. Velásquez G, Boulet P. Globalization and access to drugs. Perspectives on the WTO/TRIPS Agreement. Health Economics and Drugs, EDM Series No.7. Geneva: World Health Organization; 1999. WHO/DAP/98.9 revised.

28. Correa CM. The Uruguay Round and drugs. Geneva: World Health Organization Task Force on Health Economics; 1997. WHO/TFHE/97.1.

29. WHO. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products. A manual for a drug regulatory authority. Regulatory Support Series No.5. Geneva: World Health Organization; 1998. WHO/DMP/RGS/98.5.

30. The Interagency Pharmaceutical Coordination (IPC) Group. Operational principles for good pharmaceutical procurement. Interagency document. Geneva: World Health Organization; 1999. WHO/EDM/PAR/99.5.

31. MSH. International drug price indicator guide. Washington D.C.: Management Sciences for Health; 1999. (Annual publication, in collaboration with WHO).

32. Correa C. Integrating public health concerns into patent legislation in developing countries. Geneva: South Centre; 2000.

33. WHO. Globalization, TRIPS and access to pharmaceuticals. WHO Policy Perspectives on Medicines No.3. Geneva: World Health Organization; 2001. WHO/EDM/2001.2.

34. WHO. Health reform and drug financing. Selected topics. Health Economics and Drugs EDM Series No.6. Geneva: World Health Organization; 1998. WHO/DAP/98.3.

35. WHO. The world health report 2000. Geneva: World Health Organization; 2000.

36. Normad C, Weber A. Social health insurance: a guidebook for planning. Geneva: World Health Organization/International Labour Organisation; 1994. WHO/SHS/NHP/94.3.

37. Bennet S, Creese A, Monash R. Health insurance schemes for people outside formal sector employment. Geneva: World Health Organization; 1998. WHO/ARA/CC/98.1.

38. UNAIDS/UNICEF/MSF/WHO. Essential drugs used in the care of people living with HIV: sources and prices. Geneva/Copenhagen: Joint United Nations Programme on HIV/AIDS, United Nations Children’s Fund, Médecins Sans Frontières, World Health Organization; 2000. Also available at: http://www.who.int/medicines/docs/pagespublications/hiv_relatedpub.htm

39. WHO. Establishing or maintaining domestic production of pharmaceuticals in developing countries: advantages and disadvantages. EDM technical briefing paper. Geneva: World Health Organization. In preparation.

40. ITC in collaboration with WHO. The Market News Service (MNS) for pharmaceutical starting materials/essential drugs. Geneva: International Trade Centre; monthly edition.

41. WHO. Interagency guidelines for accepting or endorsing donations or discounts of single-source pharmaceuticals. Interagency guidelines. Geneva: World Health Organization. In preparation.

42. WHO. The new emergency health kit. Drugs and medical supplies for 10,000 people for approximately 3 months. 2nd ed. Interagency document. Geneva: World Health Organization; 1998. WHO/DAP/98.10.

43. WHO. Guidelines for the safe disposal of unwanted pharmaceuticals in and after emergencies. Interagency guidelines. Geneva: World Health Organization; 1999. WHO/EDM/PAR/99.2.

44. WHO. Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. Geneva: World Health Organization; 1999. WHO/EDM/QSM/99.1.

45. WHO. National drug regulatory legislation: guiding principles for small drug regulatory authorities. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth Report. WHO Technical Report Series No.885, Annex 8. Geneva: World Health Organization; 1999.

46. WHO. Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1. Geneva: World Health Organization; 1997. (Volume 2, 1999).

47. WHO. Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. Geneva: World Health Organization; 1997. WHO/PHARM/82.4, Rev.5.

48. WHO. Provisional guidelines on the inspection of pharmaceutical manufacturers. In: WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. WHO Technical Report Series No.823, Annex 2. Geneva: World Health Organization; 1992. Also reproduced in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 2. Geneva: World Health Organization; 1999.

49. WHO. Guidelines for inspection of drug distribution channels. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fifth Report. WHO Technical Report Series No.885, Annex 6. Geneva: World Health Organization; 1999. Also reproduced in Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 2. Geneva: World Health Organization; 1999.

50. WHO. Good manufacturing practices for pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-second Report. WHO Technical Report Series No. 823, Annex 1. Geneva: World Health Organization; 1992.

51. WHO. Guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth Report. WHO Technical Report Series No.863, Annex 10. Geneva: World Health Organization; 1996.

52. WHO. National laboratories for drug quality surveillance and control. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Twenty-ninth Report. WHO Technical Report Series No.704, Annex 1. Geneva: World Health Organization; 1984.

53. WHO. Good laboratory practices in governmental drug control laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth Report. WHO Technical Report Series No.748, Annex 1. Geneva: World Health Organization; 1987.

54. WHO. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth Report. WHO Technical Report Series No. 863, Annex 9. Geneva: World Health Organization; 1996. Also reproduced in: Quality assurance of pharmaceuticals. A compendium of guidelines and related materials, Volume 1. Geneva: World Health Organization; 1997.

55. CIOMS/WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: Council for International Organizations of Medical Sciences and World Health Organization; 1993.

56. Tan-Torres Edejer T. North-South research partnerships: the ethics of carrying out research in developing countries. BMJ 1999; 319: 438-441.

57. World Medical Association. Declaration of Helsinki. Available at: http://www.wma.net Also reproduced in: WHO Drug Information 2000; 14 (3): 160-162.

58. WHO. Ethical criteria for medicinal drug promotion. Geneva: World Health Organization; 1988.

59. WHO. How to investigate drug use in health facilities. Selected drug use indicators. EDM Research Series No.7. Geneva: World Health Organization; 1993. WHO/DAP/93.1.

60. WHO. How to investigate drug use in communities. EDM Research Series No. 2. Geneva: World Health Organization. Revised version in preparation.

61. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy and Planning 2001; 16(1): 13-20.

62. De Vries TPGM, Henning R, Hogerzeil HV, Fresle DA. Guide to good prescribing. A practical manual. Geneva: World Health Organization; 1994. WHO/DAP/94.11.

63. Hogerzeil HV, Barnes KI, Henning RH, Kocabasoglu YE, Möller H, Smith AJ, Summers RS, de Vries TPGM. Teacher’s guide to good prescribing. Geneva: World Health Organization. In print.

64. Kafle KK, Gartoulla RP. Self-medication and its impact on essential drugs schemes in Nepal. A socio-cultural research project. EDM Research Series No.10. Geneva: World Health Organization; 1993. WHO/DAP/93.10.

65. German Foundation for International Development (DSE). Drug information centres in developing countries. In: Report of an international seminar on improving drug information systems in developing countries, 28 May - 3 June 1995. Berlin: DSE; 1995.

66. Fresle D, Wolfheim C. Public education in rational drug use. Geneva: World Health Organization; 1997. WHO/DAP/97.5.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014